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Background: MicroRNAs (miRNAs) are a large group of post-transcriptional gene regulators that potentially play a
critical role in tumorigenesis. Increasing evidences indicate that miR-744 deregulated in numerous human cancers
including hepatocellular carcinoma (HCC). However, its role in HCC carcinogenesis remains poorly defined. In this
study, we investigated the roles of miR-744 in tumor growth of HCC.
Methods: Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was conducted to detect the
expression of miR-744 and Immunohistochemistry was performed to detect expression of c-Myc in HCC specimens
and adjacent normal tissues. The biological functions of miR-744 were determined by cell proliferation and cell cycle
assay. Furthermore, cell lines transfected with miR-744 mimics were analyzed in vitro. Luciferase reporter assays was
performed to confirm whether miR-744 regulated the expression of c-Myc.
Results: Our results showed that the expression of miR-744 was frequently down-regulated in both HCC tissues
and cells. Furthermore, restoration of miR-744 in HCC cells was statistically correlated with decrease of cell growth
and restored G1 accumulation. Luciferase assay and Western blot analysis revealed that c-Myc is a direct target of
miR-744. Down-regulation of miR-744 and up-regulation of c-Myc were detected in HCC specimens compared with
adjacent normal tissues. Moreover, restoration of miR-744 rescues c-Myc induced HCC proliferation.
Conclusions: Our data suggest that miR-744 exerts its tumor suppressor function by targeting c-Myc, leading to
the inhibition of HCC cell growth. miR-744 may serve as a potentially useful target for the miRNA-based therapies
of HCC in the future.
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miRNAs are one family of small (~22 nucleotides), non-
coding RNAs which play an important role in regulating
diverse biological processes, such as proliferation, differ-
entiation, apoptosis, development and metabolism [1].
Increasing evidences indicate that some miRNAs act as
either tumor suppressors or oncogenes in the tumori-
genesis of cancer and have been potential biomarkers for
tumor therapy, diagnosis, prognosis [2-5].* Correspondence: zzj6600@126.com; dongyixing@hotmail.com
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unless otherwise stated.HCC is one of the most common cancers in the world
which accounts for ~700 000 deaths annually and with
an estimated 21 000 new diagnosed cases [6]. Much ef-
forts have been spent on the study of the biological
mechanism of HCC cells to develop effective treatment
strategies. Altered miRNA expression in HCC has been
found in different studies. Several deregulated miRNAs
in HCC such as miR-195 [7], miR-101 [8], miR-122 [9],
miR-221 [10], miR-224 [11] miR-223 [12], miR-21 [13]
and miR-199 [14] have been shown to regulate cell
growth, apoptosis, migration and invasion. These findings
suggest that deregulation of miRNA may be associated
with tumorigenesis of HCC. More extensive investigations
are required to elucidate the role of miRNAs in the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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as novel biomarkers for HCC therapy, diagnosis, prognosis.
miR-744 is significantly deregulated in several cancers,
including HCC [14], colon cancer [15], breast cancer
[16], and gastric cancer [17]. Because deregulation of
miR-744 is common to a number of cancers, it has been
hypothesized that miR-744 may play an important role
in tumor development and tumorigenesis. However, the
function of miR-744 remains unclear, especially in HCC.
In our current study, we evaluated miR-744 expression
levels in 40 tumor tissues of patients with HCC and
found that miR-744 was significantly down-regulated in
HCC. Based on gain-of-function approach, we proved
that miR-744 could inhibit HCC cell proliferation
in vitro. Furthermore, c-Myc, which is usually overex-
pressed in a variety of human cancers including HCC,
was identified as a direct target of miR-744. Our findings
will help to elucidate the functions of miR-744 and their
roles in HCC tumorigenesis.
Results
miR-744 down-regulated in HCC
To determine the levels of miR-744 in HCC samples and
cell lines, total RNAs were extracted from HCC tissues
and cell lines, and the expression levels of miR-744 were
analyzed using qRT-PCR and normalized against an en-
dogenous control (U6 RNA). As shown in Figure 1A,
miR-744 was significantly decreased in HCC tissues ver-
sus adjacent normal tissues. It was also shown that miR-
744 was down-regulated in 4 HCC cell lines, compared
with 5 normal liver tissues and normal liver cell line
LO2 (Figure 1B). Taken together, our results revealed
that miR-744 was abnormally down-regulated both in
human HCC samples and cell lines.Figure 1 miR-744 is down-regulated in HCC samples and HCC cell lin
normal liver tissues by qRT-PCR, and the expression levels of miR-744 were
expression levels of miR-744 were further measured in 5 normal liver tissue
expression levels of miR-744 were normalized to U6 RNA expression for su
was set as relative expression 1. The data were subjected to Student's t-tesmiR-744 inhibits HCC growth
We then investigated the biological significance and its
underlying mechanisms of the silenced miR-744 in
HCC. Cell proliferation is a key character during tumori-
genesis. However, the association of miR-744 with HCC
cell proliferation is unknown. miR-744 mimics or nega-
tive control oligonucleotides was transiently transfected
into human HCC cell lines that have lowly endogenous
expression levels of miR-744 (Figure 1B). Expression of
miR-744 was verified by qRT-PCR. qRT-PCR results de-
termined that transfection of miR-744 restored its ex-
pression in HepG2 and SMMC-7721 cells (Figure 2A).
In cell proliferation assay, restoration of miR-744 in
HepG2 and SMMC-7721 cells resulted in significant
suppression of cell proliferation, the proliferation rate
was suppressed in HepG2 and SMMC-7721 cells after
transfection with miR-744, and the inhibitory efficiencies
were 45.8% and 36.7%, respectively (Figure 2B).
Cell cycle analysis was performed to determine whether
the effect of miR-744 on cell proliferation was due to cell
cycle arrest. The result showed that the cell cycle was
arrested in G1 phase, with 69.17% ± 8.74% of miR-744-
transfected cells in G0/G1 versus 54.02% ± 7.16% of nega-
tive control oligonucleotides-transfected cells in HepG2
cells (Figure 2C). Similar effects of miR-744 were found in
SMMC-7721 cells (Figure 2D), with 70.95% ± 8.92% of
miR-744-transfected cells in G0/G1 versus 53.32% ± 8.52%
of negative control oligonucleotides-transfected cells.
These results demonstrate that miR-744 regulates prolifer-
ation of HCC cells.
miR-744 targets c-Myc
As miRNAs function mainly through inhibition of target
genes, the target gene of miR-744 that functions in HCCes. (A) Expression of miR-744 was measured in 40 HCC samples and
normalized to U6 RNA expression for subsequent analyses. (B) The
s, normal liver cell line LO2 and 4 HCC cell lines by qRT-PCR, and the
bsequent analyses. The normalized expression of normal liver tissues
t. *p < 0.05, **p < 0.01.
Figure 2 MiR-744 restoration inhibit the viability of HCC cells. (A) miR-744 expression was quantified by qRT-PCR analysis. miR-744 mimics
restorated miR-744 expression in both HepG2 and SMMC-7721 cells. (B) Proliferation assay of HCC cells in response to miR-744 restoration. HepG2
or SMMC-7721 cells were seeded into 96-well plates and incubated in the presence of miR-744 mimics or negative control oligonucleotides.
Cell proliferationassay was done after culturing for 72 h. (C, D) Cell-cycle distribution was analyzed by FACS analysis. HepG2 (C) and SMMC-7721
(D) cells were transfected with miR-744 mimics or negative control oligonucleotides. Nocodazole (25 ng/ml) was added 24 h after transfection for
another 16 h, then the supernatant was replaced by fresh medium for 6 h. The data were subjected to Student's t-test. *p < 0.05, **p < 0.01. NC,
negative control oligonucleotides.
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newly published CLASH data [18], we found that about
402 genes were targeted by miR-744 in HEK293 cells.
Among these genes, we focus on c-Myc gene, a central
component of the MAPK/ERK pathway, which is in-
volved in many cellular processes including cell growth,
cell differentiation, apoptosis and other cellular functions
[19-21]. c-Myc is a very strong proto-oncogene and it is
often found to be up-regulated in many types of cancers
including HCC [22,23]. From the CLASH data in KEK293
cells, the potential targeting sequence for miR-744 with a
calculated energy of −24.1 kcal/mol is within the protein
coding region of c-Myc mRNA from 1162 to 1206. This is
clearly distinct from the recently reported c-Myc targeting
miR-24 [24], miR-145 [25] and let-7a [26], but is simi-
lar to miR-185-3p [27]. To confirm whether miR-744
could regulate the expression of c-Myc, we first performed
luciferase reporter assays in HEK293 cells. We created
luciferase reporter plasmid with wild type or mutant tar-
geting sequence of c-Myc mRNA (Figure 3A), which
were cotransfected with miR-744 mimics or negativecontrol oligonucleotides into HEK293 cells for 48 h,
followed by measurement of luciferase activity in trans-
fected cells. Our results showed that the reporter plasmid
with wild type targeting sequence of c-Myc mRNA caused
a significant decrease in luciferase activity in cells trans-
fected with miR-744, whereas reporter plasmid with mu-
tant sequence of c-Myc produced no change in luciferase
activity (Figure 3B). Then, we explored whether the en-
dogenous c-Myc in HCC cells was regulated similarly.
HepG2 and SMMC-7721 cells were transfected with miR-
744 mimics or negative control oligonucleotides, and
c-Myc mRNA and protein levels were examined by qRT-
PCR and western blotting, respectively. c-Myc mRNA ex-
pression was not affected by miR-744 (Figure 3C). The
level of c-Myc protein was consistently and substantially
down-regulated by miR-744 (Figure 3D).
Consistently, HCC tissues with low miR-744 showed much
higher c-Myc expression, compared with normal liver tissues
with high level of miR-744 but lower c-Myc expression
(Figure 4A,B). Taken together, our results demonstrated
that c-Myc was a direct target of miR-744 in HCC cells.
Figure 3 miR-744 directly targets and regulates c-Myc expression in HCC cells. (A) Wild-type (WT) and mutant (Mut) of putative miR-744
targeting sequences in c-Myc mRNA. Mutant sequences were shown in bold type. (B) Analysis of luciferase activity. HEK-293 cells were
cotransfected with miR-744 mimics or control oligo nucleotides, pRL-TK and firefly luciferase reporter plasmid containing putative miR-744
targeting sequences of c-Myc. pRL-TK was cotransfected as an internal control to correct the differences in both transfection and harvest
efficiencies. The firefly luciferase activity of each sample was normalized to the Renilla luciferase activity. The normalized luciferase activity
control oligo nucleotides was set as relative luciferase activity 1 respectively. (C) Effects of miR-744 mimics on the endogenous c-Myc mRNA levels.
HepG2 and SMMC-7721 cells were cotransfected with miR-744 mimics or negative control oligonucleotides. Forty-eight hours after transfection, cells
were isolated, the expression of c-Myc was analyzed by qRT-PCR. (D) Effects of miR-744 on the endogenous c-Myc protein levels. Forty-eight hours after
transfection with the miR-744 mimics or negative control oligonucleotides, HepG2 and SMMC-7721 cells were analyzed by Western blotting, with β-actin
as an internal control. The value up each lane indicates the c-Myc expression in oligonucleotides-transfected cells compared with mock-transfected
(with only transfection reagent) cells. The data were subjected to Student's t-test. *p < 0.05, **p < 0.01. NC, negative control oligonucleotides.
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proliferation
c-Myc is a nuclear transcriptional factor and most of its
targeting genes including Cyclin D1 are crucial in the
regulation of cell growth, differentiation, apoptosis and
other cellular functions [28]. We had resulted that res-
toration of miR-744 could suppress the growth and pro-
liferation of HCC cells and c-Myc was a direct target of
miR-744. So we hypothesized that miR-744 regulated cell
growth in HCC cells by targeting c-Myc. One endogenous
targets Cyclin D1 of the c-Myc in cancer cells were tested.
As expected, ecoptic c-Myc in HepG2 cells enhanced the
accumulation of Cyclin D1, while restoration the miR-744
expression in HepG2 cells partially inhibited expression of
Cyclin D1 (Figure 5A). In addition, miR-744 also inhibited
the c-Myc-dependent expression of endogenous Cyclin
D1 in SMMC-7721 cells (Figure 5B). In line with these
results, miR-744 partially alleviated c-Myc-induced
cell proliferation in HepG2 and SMMC-7721 cells(Figure 5C and D). Taken together, these results dem-
onstrated that miR-744 could regulate HCC cells
growth partially through targeting c-Myc.
Discussion
In this study, we focused on miR-744 which was de-
creased in HCC tissues and four HCC cell lines. Our re-
sults agreed with the previously study in HCC [14].
Additional experiments demonstrated that restoration of
miR-744 significantly decreased the proliferation of the
HepG2 and SMMC-7721 cell lines. The decreased pro-
liferation of the HCC cell lines resulted from inhibiting
cell cycle progression in vitro. Moreover, we identified
c-Myc, which is an oncogenic transcription factor, as a
direct and functional target of miR-744 in HCC cells.
It has been well established that miRNAs play critical
roles in the development, differentiation, proliferation,
apoptosis, invasion and metastasis of a variety of can-
cers. Recently, deregulation of miRNA in cancer cells
Figure 4 Expression analyses of miR-744 and c-Myc in HCC tissues. (A) Analysis of c-Myc expression in five HCC tissues and adjacent normal
tissues by IHC. Brown signal in IHC was considered as positive staining for c-Myc. Scale bar = 50 μm. (B) Analysis of miR-744 expression in the
same HCC tissues and adjacent normal tissues by qRT-PCR. The data were subjected to Student's t-test. *p < 0.05, **p < 0.01.
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investigated [2,29,30]. miR-744 has been reported to
be frequently deregulated in various kinds of cancers.
miR-744 was able to inhibit the proliferation of breast
cancer cells by targeting eukaryotic translation elong-
ation factor 1A2 (eEF1A2) [16]. Previous studies iden-
tified a panel of serum miRNAs including miR-744 as
potential biomarkers for gastric cancer detection [17].
Long-term overexpression of miR-744 may cause chromo-
somal instability and inhibit tumor growth by prolonging
activation of Ccnb1 in mouse [31]. However, the role of
miR-744 in cancers especially in HCC is not very much
known. In the present study, our data show that compared
with adjacent normal liver tissues, miR-744 expression
in HCC is significantly down-regulated, suggesting thatmiR-744 is a candidate tumor suppressor in the pathogen-
esis of HCC.
c-Myc is a nuclear transcriptional factor and most of
its targeting genes are crucial for ribosome biogenesis
and protein synthesis including Cyclin D1 [32-34], which
are indispensable for cell growth, proliferation, and de-
velopment. For its biological importance, c-Myc is care-
fully regulated at transcriptional, post-transcriptional,
translational and posttranslational levels [19]. However,
the level of c-Myc are highly expressed in most human
cancers including HCCs. Although a variety of protein-
associated mechanisms have been shown to be involved
for its highly expression in cancers [19], several miRNA
such as miR-24, miR-22, miR-145, let-7a,miR-34a, miR-
185-3p were reported as regulators of c-Myc [24]. These
Figure 5 miR-744 inhibits c-Myc-dependent activity and cell proliferation in HCC cells. (A, B)miR-744 inhibits c-Myc-dependent transcription
of the c-Myc target gene Cyclin D1. HepG2 and SMMC-7721 cells were transfected with miR-744 and/or pGL3-c-Myc, and the expression
of c-Myc and Cyclin D1 were analyzed by Western blotting. The value up each lane indicates the protein expression with β-actin as an
internal control. (C, D) miR-744 inhibits c-Myc-dependent cell proliferation. HepG2 and SMMC-7721 cells were transfected with miR-744
and/or pGL3-c-Myc, and cells proliferation was measured by CCK-8 analysis. The data were subjected to Student's t-test. *p < 0.05.
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with different mechanisms. miR-24, miR-22, miR-145,
let-7a and miR-34a bind to distinct seeding sequences
residing in the 3′-UTR of c-Myc mRNA. However,
miR-185-3p and miR-744 in our study have been reported
to target protein-coding sequence of c-Myc mRNA.
Our findings demonstrated that miR-744 was frequently
down-regulated in HCC cell lines and clinical samples.
Our data demonstrated for the first time that restoration
of miR-744 significantly inhibited HCC cells proliferation
through down-regulating c-Myc protein level. Moreover,
miR-744 down-regulated c-Myc protein level through tar-
geting its protein-coding sequence but not 3′UTR. Our
identification of c-Myc as a target of miR-744 provides
new insights into the mechanisms underlying HCC prolif-
eration and miR-744 have potential as novel therapeutic
targets for the treatment of HCC.
Conclusions
In summary, our data show that miR-744 is down-regulated
in HCC tissues compared with normal liver tissues. miR-
744 directly downregulates c-Myc and inhibits HCC cell
proliferation. These data indicate that miR-744 may serve
as a new target for cancer therapy.Materials and methods
Tissue samples and cell lines
Forty primary HCC tissues and adjacent normal liver tis-
sues were obtained from the Department of General
Surgery, Taizhou First People's Hospital (Zhejiang, China)
for qRT-PCR analysis. The histopathological diagnosis
of HCC was confirmed by the hospital’s Pathology
Department according to the criteria of the World Health
Organization after the operation. All tissue samples were
from the surgical removal and immediately snap frozen in
liquid nitrogen and stored in liquid nitrogen until use.
The study protocol was approved by Ethical Committee of
Biomedicine Research from General Hospital of Taizhou
Military Command. Informed consent was obtained from
all patients. All patients had no history of radiotherapy or
chemotherapy preoperatively. All clinicopathologic and
biological data were available for those patients. Patients’
characteristics of clinical-pathologic features were listed in
Table 1. Additionally, five normal liver tissues were ob-
tained from adjacent liver tissues of contusion and lacer-
ation in traumatic liver injury patients. All HCC cell lines
(HepG2, SMMC-7721, QGY-7703, BEL-7402) and human
hepatic cell lines LO2 used in this study were purchased
from the cell bank of the Chinese Academy of Sciences
Table 1 Patients’ characteristics of clinical-pathologic
features
Characteristics No. of patients (n = 40) Percent (%)
Age at diagnosis (year)
≤ 40 8 20.0





≤ 2 5 12.5
> 2 and ≤ 5 24 60.0
> 5 11 27.5
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10% FBS. HEK293 cells were purchased from ATCC and
grown were cultured in DMEM media containing 10%
FBS. Cells were maintained at 37°C in a humidified atmos-
phere with 5% CO2.
RNA isolation and qRT-PCR
Total RNA was isolated from HCC tissues, adjacent nor-
mal liver tissues, HCC cell lines and human hepatic cell
lines LO2 using Trizol according to the manufacturer’s in-
structions. qRT-PCR-based detection of mature miR-744
was performed as described previously [14]. U6 small
RNA was used as an internal control for normalization
and quantification of miR-744 expression. All experiments
were done in triplicate. All primers were listed in Table 2.
Oligonucleotides and plasmids transfection
RNA oligos were chemically synthesized and purified by
Genepharma Co. Ltd., (Shanghai, China). Sense sequenceTable 2 All primers used in this study
Name Primer Sequence
U6 F 5′ - CTCGCTTCGGCAGCACA -3′
U6 R 5′- AACGCTTCACGAATTTGCGT -3′
c-Myc (WT) F 5′-AAACTAGTGAGCTCGCCCAAGTCCTG -3′
c-Myc (WT) R 5′-GGAAGCTTAGAGAAGGCGCTGGAG -3′
c-Myc (MUT) F 5′-AAACTAGTGAGCTCCGGGATCTGGTG -3′
c-Myc (MUT) R 5′-GGAAGCTTAGAGAAGGCGCTGGAG -3′
c-Myc (pGL3) F 5′-AAAGGTACCATGCCCCTCAACGTTAGCTTCACC-3′
c-Myc (pGL3) R 5′-AAACTCGAGTTACGCACAAGAGTTCCGTAGC-3′
miR-744 RT 5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCAC
TGGATACGATGCTGT-3′
miR-744 F 5′- AATGCGGGGCTAGGGCTA-3′
miRNA Universal R 5′- GTGCAGGGTCCGAGGT-3′
Abbreviations: RT, reverse-transcription primer; F, forward primer; R, reverse
primer; WT, wild type; MUT, mutant.of human miR-744 mimics was 5′- UGC GGG GCU
AGG GCU AAC AGC A -3′ and antisense sequence was
5′- UGC UGU UAG CCC UAG CCC CGC A-3′. Nega-
tive control oligonucleotides was 5′-AAU UCU CCG
AAC GUG UCA CTT-3′ and 5′-GUG ACA CGU UCG
GAG AAU UTT-3′. The transfections were performed
with INTERFERin reagent (Polyplus-transfection). The
final concentration of miRNA was 50 nM.
To generate pGL3-c-Myc constructs, the sequence of
c-Myc mRNA was amplified by the primers listed in
Table 2. The fragments were inserted into pGL3 with
the designed cutting sites: KpnI and XhoI. The transfec-
tions were performed with Lipofectamine 2000 reagent
(Invitrogen, USA). The final concentration of plasmids
was 100 ng.
Luciferase reporter assays
Luciferase reporter construct was made by cloning human
c-Myc mRNA sequence into pMIR-Report construct
(Ambion, Austin, USA). Wild type or mutant c-Myc
mRNA fragment (from 1162 to 1206) was amplified and
cloned into the luciferase repoter via SpeI and HindIII
sites. All the primers were listed in Table 2. Luciferase re-
porter assays were performed as previously [14], HEK293
cells plated in a 48-well plate were co-transfected with 50
nM single-stranded miRNA mimics or negative control
oligonucleotides, 50 ng of firefly luciferase reporter and
10 ng of pRL-TK (Promega, USA) using the JetPRIME re-
agent (Polyplus-transfection). Cells were collected 36 hours
after last transfection and analyzed using Dual-Luciferase
Reporter Assay System (Promega).Cell proliferation assay
Cell proliferation was measured using the CCK-8 assay kit
(Dojindo Corp., Japan) according to the manufacturer’s
protocol. Cells were plated into each well of a 96-well
plate and transfected with miRNA mimics or negative
control oligonucleotides. On the day of harvest, 10 μl
CCK-8 was added to 90 μl of culture medium. The cells
were subsequently incubated for 2 hr at 37°C and the op-
tical density was measured at 450 nm. Three independent
experiments were performed.Western blot
Proteins were separated on a 12% SDS-PAGE gel and
transferred onto a nitrocellulose membrane (Bio-Rad,
Hercules, USA). The membrane was blocked with 5%
non-fat milk and incubated with anti-c-Myc antibody,
anti-Cyclin D1 (Santa Cruz, CA) or anti-beta-actin anti-
body (Sigma, CA, USA). After being washed extensively,
a goat anti-mouse secondary antibody (Pierce, IL, USA)
was added to the system. The proteins were detected
using ECL reagents (Pierce).
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Paraffin-embedded tissue sections were deparaffinized in
xylene and rehydrated in graded series of ethanols
followed by heat induced epitope retrieval in citrate buf-
fer (PH 6.0). c-Myc expression were detected using anti-
c-Myc polyclonal antibody (Santa Cruz, CA; 1:80). After
incubation with a biotinylaed secondary antibody and DAB
(Dako, Carpenteria, CA), the slides were rinsed and coun-
terstained with Mayer’ hematoxylin.
Statistical analysis
All statistical analyses were carried out using the SPSS
16.0 statistical software package. Continuous variables were
expressed as mean ± SEM. Differences between groups
were calculated with Student’s t test. A two-tailed P value
test was used with a P value of < 0.05 considered statisti-
cally significant.
Abbreviations
HCC: Hepatocellular carcinoma; mRNA: Messenger RNA; qRT-PCR: Quantitative
reverse-transcription polymerase chain reaction; miRNA: MicroRNA;
IHC: Immunohistochemistry.
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